Volta Labs

Executive Summary

Volta Labs, based in Cambridge, MA, is pioneering automated sample preparation for next-generation sequencing (NGS) with its Callisto™ platform. By leveraging digital microfluidics, Callisto enables true walk-away automation for library preparation and target enrichment, addressing critical bottlenecks in NGS workflows. The platform promises improved performance, scalability, and consistency across diverse sample types and sequencing technologies. As NGS adoption expands in clinical diagnostics and research, Volta's solution reduces labor costs and human error, positioning it as a key enabler of high-throughput genomics. The company, founded in 2018, is privately held and has not disclosed funding details, but its innovative approach targets a rapidly growing market projected to exceed $20 billion by 2030. Volta's focus on automation aligns with industry trends toward standardization and efficiency, making it a compelling player in the genomics applications space.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of Callisto platform in new markets (e.g., clinical labs)65% success
• Q4 2026Strategic partnership with a major sequencing instrument manufacturer50% success
• Q2 2027Series B or later funding round to scale operations70% success